CA-SCIENTIST.COM
11.7.2024 13:56:27 CEST | Business Wire | Press release
BioPharmCatalyst (BPC), a division of Scientist.com, today announced that members with an “Elite” and “Elite Plus” subscription now get full access to Trial Insights, which curates and enriches publicly available data from clinicaltrials.gov and other data sources. Trial Insights creates filterable, customizable dashboards on clinical trial status, sponsors and new medicines, enabling investors to make smarter, data-driven decisions.
“The ability to track drugs throughout their development cycle based on catalyst events not only drives biotech investor decision making, but also helps scientists keep up to date with clinical trials in their research areas,” stated John Gagliano, Senior Director, BioPharmCatalyst. “The addition of Trial Insights provides subscribers with real time insight into clinical trial results that were previously difficult and time consuming to gather through publicly available sources.”
BPC equips investors in the biotech and pharmaceutical industries with a comprehensive suite of tools for making informed investment decisions. These include an FDA calendar, a PDUFA calendar, an earnings calendar, the latest IPO information and a company’s cash database. With Trial Insights, Elite and Elite Plus subscribers can closely monitor ongoing clinical trials being conducted around the world in real time through their existing account.
To access BioPharmCatalyst’s investing tools and start a free trial, visit www.biopharmcatalyst.com. To learn more about Trial Insights, visit www.biopharmcatalyst.com/trial-insights.
About Scientist.com
Scientist.com is the world's leading AI-enabled marketplace for scientific research. The marketplace simplifies drug discovery research, saving time and money and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 100 biotechnology companies and the US National Institutes of Health (NIH).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711495417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 10:00:00 CEST | Press release
New SH602FA and SE505FE smart modules combine Android 16 with integrated wireless connectivity to accelerate industrial and commercial IoT development Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance
Queue-it Announces Majority Investment from THL Partners18.8.2026 09:00:00 CEST | Press release
Partnership will support continued product innovation and global expansion for the online traffic orchestration platform Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations &
THL Partners opkøber danske Queue-it af GRO og investerer i næste fase af den spændende vækstrejse18.8.2026 09:00:00 CEST | Pressemeddelelse
Partnerskabet skal understøtte fortsat produktinnovation og global ekspansion for teknologiplatformen til orkestrering af onlinetrafik. Queue-it, global leverandør af løsninger til orkestrering af onlinetrafik, annoncerede i dag, at virksomheden har indgået en endelig aftale om en majoritetsinvestering fra THL Partners ("THL"), et førende investeringsselskab med fokus på mellemstore vækstvirksomheder. Sammen vil THL og Queue-it fokusere på at accelerere produktinnovation og udvide virksomhedens globale rækkevidde. Queue-it blev grundlagt i Danmark i 2010 og har hovedkontor i København men servicerer i dag de største brands og organisationer i hele verden. Virksomheden hjælper virksomheder og offentlige organisationer med at håndtere spidsbelastninger i onlinetrafik, beskytte digital infrastruktur, reducere bot-aktivitet og misbrug samt sikre fair og pålidelig adgang til kritiske digitale tjenester. Platformen anvendes af organisationer over hele verden inden for blandt andet billetsalg
Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 09:00:00 CEST | Press release
Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom